

LABETALOL

PRESENTATION:	Ampoules containing 100mg/20ml (5mg/ml)
INDICATION:	Hypertension. Labetalol has alpha and beta receptor blocking activity.
DOSE AND ADMINISTRATION:	<p>ICU STANDARD INFUSION</p> <p>For central administration, labetalol is administered undiluted e.g. 200mg in 40ml.</p> <p>For peripheral administration, dilute to 1mg/ml in glucose 5% or sodium chloride 0.9% e.g. 500mg in 500ml.</p> <p>Initially 15mg/hr, titrated to the required level. Usual maximum rate is 120mg/hour, but higher doses of up to 160mg/hr can be used if necessary.</p> <p>Glucose 5% is the preferred diluent. Sodium Chloride 0.9% may be used but is not licensed for all available preparations.</p>
CONCENTRATION:	<p>Central administration: 5mg/ml (unlicensed)</p> <p>Peripheral administration: 1mg/ml</p>
STABILITY:	Physically and chemically stable for 24hours at room temperature. Protect from light.
ADDITIONAL INFORMATION:	<p>Labetalol has a low pH and may cause venous irritation and tissue damage in cases of extravasation. If a central venous access device is unavailable, administer via a large peripheral vein monitoring insertion site closely. Resite cannula at first signs of inflammation.</p> <p>Use a separate lumen to avoid other infusions affecting the infusion rate.</p>

References

1. Labetalol Hydrochloride 5mg/ml solution for injection, EMC, RPH Pharmaceuticals AB, Updated March 2019, Accessed December 2020.
https://www.medicines.org.uk/emc/product/9165/smpc#PHARMACODYNAMIC_PROPS
2. Labetalol 5mg/ml solution for injection/infusion, EMC, Bowmed Ibisqus Limited, Updated November 2019. Accessed December 2020.
<https://www.medicines.org.uk/emc/product/10831/smpc#gref>
3. Labetalol hydrochloride, The UK Injectable Medicines Guide, medusa. Accessed December 2020. <https://medusa.wales.nhs.uk/IVGuideDisplayNewFormat.asp>

Critical Care Guidelines
FOR CRITICAL CARE USE ONLY

Title: LABETALOL	
ID:	Authors: Mairi Cromarty
Category:	Document Version: 5.0
Status: Final	Review Date: February 2023
Authoriser :Lothian Critical Care QIT Editorial Board.	Authorisation date: February 2021
Date added to Intranet: February 2021	
Key Words	
Comments	